Please select the option that best describes you:
How do you discuss the importance of ongoing lifestyle-based interventions when starting a GLP-1 agonist for medically relevant obesity (i.e., with comorbid conditions)?
As seen in the new ADA guidelines on the Standards of Care in Obesity and Weight management